Biotech Profile (Nasdaq: MDCX) Hits Our Radar As 5 Explosive Potential Catalysts Are On Watch

In today's dynamic life sciences field

*Disseminated on behalf of Medicus Pharma Ltd. Biotech Profile (Nasdaq: MDCX) Hits Our Radar As 5 Explosive Potential Catalysts Are On Watch *Click Here To Get Our Alerts Faster Via SMS* November 11th Dear Reader, In today’s dynamic life sciences field, few innovators are tackling critical treatment gaps as decisively as this company. Through its subsidiary, it's advancing a dissolvable microneedle patch that delivers chemotherapy directly into tumors, offering new potential for treating basal cell carcinoma.  Active clinical trials in the U.S. and UAE highlight its push toward gentler, surgery-less cancer care. Strategic acquisitions, including a UK biotech targeting prostate cancer, further strengthen its position. Focused on faster, data-driven innovation, the company is redefining standards across human and veterinary health. And with a float of fewer than 7Mn, a recently completed acquisition, and multiple analyst targets suggesting massive upside potential, this Nasdaq profile has just overtaken my watchlist once again. Take a moment to consider this idea for your radar: *Medicus Pharma Ltd. (Nasdaq: MDCX)* Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents. And based on several potential catalysts, (Nasdaq: MDCX) has pushed its way to the top of my watchlist. Take a look: No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally. No. 3 - An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit!). No. 4 - Medicus Pharma Expands Global Reach With UAE Sknjct-004 Phase 2 Clinical Study Advancement Milestone. No. 5 - A Game-Changing Acquisition Is Completed! But more on those in a second... Company Breakdown - Medicus Pharma Ltd. (Nasdaq: MDCX) Medicus Pharma Ltd. specializes in rapidly moving forward the clinical development of cutting-edge therapeutic solutions within the biotech and life sciences sector. About SkinJect - Medicus Pharma's (Nasdaq: MDCX) Wholly Owned Subsidiary A novel non-invasive regimen to treat skin cancer; especially Basal Cell Carcinoma. SkinJect Inc. is a development stage biotechnology life sciences company focused on commercializing novel treatment for non-melanoma skin cancer, especially basal cell carcinoma, using a patented dissolvable doxorubicincontaining microneedle arrays (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells. The relevant US Patents were granted to University of Pittsburgh and Carnegie Mellon University in 2018. SkinJect Inc. secured exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. The company attempts to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting. SkinJect Inc. has completed a Phase I study in March 2021 for participants with superficial and nodular Basal Cell Carcinoma (BCC). In January 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study that is expected to randomize up to 60 patients. Patient recruitment began in August 2024 in 9 sites across the United States. A positively trending interim analysis in March 2025 showed more than 60% complete clinical response. In April 2025, IRB approved an increase in the number of patients from 60 to 90. SkinJect Clinical Development Outlook The SkinJect Value Proposition 1. Innovative Microneedle Patch Technology: The company aims to provide an alternative to an invasive, painful, but effective treatment commonly called Mohs Surgery, by providing an efficacious, painless and easy to administer treatment in an office setting. Patented technology for non-invasively treating skin cancer using cellulose-based microneedles to deliver cancer drugs directly to the tumor site Exclusive worldwide development and commercialization rights from University of Pittsburgh and Carnegie Mellon University in April 2016. 2. Market Potential: BCC is the most common and fastest-growing cancer globally. >US$15Bn market for skin cancer treatments in North America by 2030. (1) Potential for further market expansion and penetration by SkinJect’s novel treatment approach. 3. Positive Clinical Trial Results: Phase 1 trial completed March 2021, demonstrating safety and tolerability. In Q1 2024 a Phase 2 IND clinical protocol was submitted to the FDA for a randomized, controlled, double-blind, multicenter study. In Q3 2024 Phase 2 enrollment began. In Q1 2025 conducted interim analysis after 50% patient recruitment. In Q2 2025, IRB approved to increase number of patients from 60 to 90. 4. Seasoned Leadership and Board: Management team with public company experience. Board includes industry veterans and experts in oncology and drug development. About Recent Acquisition: Antev Ltd. Antev Ltd. (“Antev”) is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, a potentially first in market product for high-risk prostate cancer patients and patients with first acute urinary retention (AUR) episodes due to enlarged prostate. Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. Teverelix: A Next-Gen GnRH Antagonist Teverelix is being developed to compete with or improve upon current GnRH antagonists like Degarelix and Relugolix as well as agonists. What sets Teverelix apart is the potential for: Rapid onset of testosterone suppression and prostate shrinkage Avoidance of testosterone flare versus agonists A longer-acting injection schedule (possibly every 6 weeks) Potential for subcutaneous and intra-muscular delivery without daily dosing (vs. Relugolix’s daily oral use) Due to superior formulation, ISRs potentially significantly milder compared to Degarelix What's Next for Teverelix? Grab Key Sources: MDCX Presentation. MDCX Website. ----- And as I mentioned previously, (Nasdaq: MDCX) has several potential catalysts that could generate breakout buzz. Check them out: No. 1 MDCX Potential Catalyst - A Low Float Could Create The Environment For Heightened Volatility. According to info from the Finviz website, MDCX has a fairly low float. The website reports this profile to have roughly 6.38Mn shares in its float. Why is that important? It's important on one crucial level. Volatility potential. If positive company news appears towards the end of 2025, could it provide a breakout spark when paired with the volatility potential of this low float? ----- No. 2 MDCX Potential Catalyst - MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally. Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC) lesions over lifetime PHILADELPHIA, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SKINJECT™, the Company’s investigational doxorubicin containing microneedle arrays (D-MNA) for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome. Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the Food and Drug Administration (FDA) to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SKINJECT™ under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SKINJECT™ in this rare disease population. SKINJECT™, is a novel localized immunogenic investigational precision therapy focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) of the skin. Gorlin Syndrome is an inherited condition affecting approximately 1 in 31,000 people worldwide. Patients can develop hundreds to over one thousand basal cell carcinomas (BCCs) over their lifetime, often beginning in early childhood. The disease imposes not only a medical but also a physical, emotional and economic toll, requiring frequent scar producing surgeries, topical treatments and lifelong dermatologic care. “Patients with Gorlin Syndrome endure a lifelong burden of recurring skin cancers that often require repeated surgeries and disfiguring treatments,” said Dr. Raza Bokhari, Executive Chairman & CEO of Medicus. “By working together with the Gorlin Syndrome Alliance, we hope to unite clinical science, regulatory leadership and advocacy to deliver hope for individuals facing lifelong burdens of Gorlin Syndrome, reinforcing our mission to deliver targeted innovation where medical need is greatest.” ... Read the full article here. ----- No. 3 MDCX Potential Catalyst - An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit!). Check out what MarketBeat is reporting: As of Tuesday's close, MDCX had 6 analyst targets pointing to a significant amount of upside potential. In fact, with an average target of $23.50, MDCX could have over 900% potential upside from its closing valuation on November 11th. MarketBeat reports further that Jason Kolbert of D. Boral Capital has given MDCX a $27 target representing a potential upside over 1,000% from Tuesday's close. Additionally, the website shares Jason McCarthy of Maxim Group has provided a $20 target suggesting 700+% potential upside from Tuesday's close. Could (Nasdaq: MDCX) be undervalued from current chart levels? ----- No. 4 MDCX Potential Catalyst - Medicus Pharma Expands Global Reach With UAE Sknjct-004 Phase 2 Clinical Study Advancement Milestone. Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin Cleveland Clinic Abu Dhabi (CCAD) Is The Principal Investigator In This 36 Participant Study PHILADELPHIA, PA / ACCESS Newswire / October 22, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce the enrollment of the first patient in United Arab Emirates (UAE) SKNJCT-004 phase 2 clinical study, to non-invasively treat BCC of the skin. The study is expected to randomize thirty-six (36) patients in six sites in the UAE. In addition to Cleveland Clinic Abu Dhabi (CCAD), the study is also expected to commence patient recruitment in Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. "Treating our first BCC patient at Cleveland Clinic Abu Dhabi is an important milestone in expanding our clinical study beyond the shores of the United States," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "Non melanoma Skin diseases, especially BCC is not just an American problem but a global challenge which we believe represents more than US$2Bn in potential market opp." ... Read the full article here. ----- No. 5 MDCX Potential Catalyst - A Game-Changing Acquisition Is Completed! Medicus Pharma Ltd. Completes Acquisition of Antev Limited Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~US$6Bn in potential market opp. Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), ..., and Antev Limited ("Antev"), a UK-based clinical-stage drug development company, announced today that Medicus has acquired 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately US$2.97Mn in ca-sh and 1,603,164 common shares of Medicus, pursuant to the previously announced securities exchange agreement among Medicus, Antev and certain securityholders of Antev, dated as of June 29, 2025, as amended. Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate. Antev's former shareholders will be entitled to receive up to approximately US$65Mn in additional contingent consideration tied to potential future FDA Phase 2 and New Drug Application approvals. Following the completion of the acquisition, Patrick J. Mahaffy, a veteran pharma executive and the former chairman of Antev, was unanimously appointed to Medicus's board of directors. Mr. Mahaffy is also the former CEO of both Clovis Oncology (NASDAQ: CLVS) and Pharmion Corporation (NASDAQ: PHRM). ... "We are delighted to complete the acquisition of Antev, which not only adds strategic depth to our drug development pipeline but also strengthens our team, both at the board and management level," stated Dr. Raza Bokhari, Medicus's Executive Chairman & CEO. "We believe, Teverelix, a next generation GnRH antagonist, is well positioned to become a first in class product to prevent acute urinary retention relapse due to enlarged prostate, and to treat advanced prostate cancer in patients with high cardiovascular risk profile, collectively representing approximately US$6Bn in potential market opp." ... Read the full article here. ----- (Nasdaq: MDCX) Recap - These 5 Potential Breakout Catalysts Lead The Way No. 1 - A Low Float Could Create The Environment For Heightened Volatility. No. 2 - MDCX Leads Innovative Collaboration Advancing Compassionate SKINJECT Access Globally. No. 3 - An Average Of 6 Analyst Targets Suggest Major Upside Potential (Triple-Digit!). No. 4 - Medicus Pharma Expands Global Reach With UAE Sknjct-004 Phase 2 Clinical Study Advancement Milestone. No. 5 - A Game-Changing Acquisition Is Completed! ----- Medicus Pharma Ltd. (Nasdaq: MDCX) is on my radar as coverage is officially initiated. Be on the lookout for updates coming shortly. Sincerely, Jaks Swift Fierce Editorial Writer (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 11/11/2025 and ending on 11/12/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid ninety thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (MDCX:US). Please see important disclosure information here: https://fierceinvestor.com/disclosure/mdcx-vkc4o/#details

Fierce | 4834 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Update Profile | Constant Contact Data Notice